Aldeyra Therapeu (ALDX)

Feb 4, 2025, 7:00 AM EST - 18 days ago

Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Dec 26, 2024, 4:04 AM EST - 2 months ago

Aldeyra Therapeutics: Key Inflection Point Ahead

Dec 2, 2024, 7:00 AM EST - 2 months ago

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Nov 18, 2024, 7:00 AM EST - 3 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Nov 14, 2024, 7:00 AM EST - 3 months ago

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 14, 2024, 5:31 AM EST - 3 months ago

Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects

ABBV

Oct 31, 2024, 7:00 AM EDT - 4 months ago

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Oct 3, 2024, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Sep 5, 2024, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 3:49 PM EDT - 6 months ago

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

ABBV

Aug 8, 2024, 12:30 PM EDT - 7 months ago

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

Aug 8, 2024, 7:00 AM EDT - 7 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aug 7, 2024, 4:01 PM EDT - 7 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Jun 20, 2024, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Jun 13, 2024, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Jun 12, 2024, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics to Host Investor Roundtable Q&A

Jun 10, 2024, 1:25 PM EDT - 9 months ago

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

May 29, 2024, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

Apr 25, 2024, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Apr 18, 2024, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Mar 28, 2024, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Mar 24, 2024, 12:46 AM EDT - 11 months ago

Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

ABBV

Feb 6, 2024, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 28, 2024, 2:56 AM EST - 1 year ago

Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

Jan 4, 2024, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Dec 19, 2023, 7:00 AM EST - 1 year ago

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Dec 18, 2023, 4:01 PM EST - 1 year ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Nov 27, 2023, 4:07 PM EST - 1 year ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Nov 1, 2023, 7:05 AM EDT - 1 year ago

Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap

Oct 16, 2023, 11:50 AM EDT - 1 year ago

Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive' issues with NDA for dry-eye disease treatment

Sep 29, 2023, 12:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the Firm

Sep 28, 2023, 5:00 AM EDT - 1 year ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Sep 26, 2023, 11:45 AM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Sep 22, 2023, 7:44 PM EDT - 1 year ago

Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash

Sep 22, 2023, 1:15 PM EDT - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Aug 22, 2023, 11:05 AM EDT - 1 year ago

Investors who lost over $100,000 with Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 2022 and June 2023 should contact the Shareholders Foundation in connection with Lawsuit

Aug 3, 2023, 5:30 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

Aug 3, 2023, 12:46 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

Jul 10, 2023, 12:49 AM EDT - 1 year ago

Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap

Jul 6, 2023, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum

Jun 29, 2023, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa